Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

NCT06931275
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
EMR-based BPA model, Placebo (EMR-based without BPA model)
Other · Behavioral
Lead sponsor
T1D Exchange, United States
Other
Eligibility
2 Years to 95 Years
Enrollment
1,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 31, 2026, 3:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

NCT02101853
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 3:34 PM EDT
Terminated Phase 2 Interventional

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

NCT00100737
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
interleukin-2, rituximab
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Oct 31, 2026, 3:34 PM EDT
Completed No phase listed Observational

Patient-Centered Assessment of Symptoms and Outcomes

NCT03952624
View directory record Official record
Conditions
Fatigue, Cancer, CFS, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lupus, Systemic Lupus Erthematosus, Sjogrens
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 3:34 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Weekly Isotretinoin vs Tetracycline for Moderate Acne

NCT06225570
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin, Tetracycline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 31, 2026, 3:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Speech Motor Learning and Retention (Aim 1)

NCT06467305
View directory record Official record
Conditions
Speech
Interventions
continuous theta-burst stimulation (cTBS), Adaptation
Device · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Sargramostim in Patients With COVID-19

NCT04411680
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Sargramostim, Standard of care
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fullerton, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

NCT04453202
View directory record Official record
Conditions
Healthy
Interventions
RSV Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diaphragm Function and Diver Endurance

NCT04679402
View directory record Official record
Conditions
Respiratory Muscles
Interventions
Carbon monoxide 200 ppm in air
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00726739
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
aldesleukin, allogeneic large multivalent immunogen vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 2Phase 3 Interventional

The Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis

NCT05367271
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Botulinum Toxin A, Dexamethasone
Drug
Lead sponsor
Western Institute for Veterans Research
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 31, 2026, 3:34 PM EDT
Recruiting Phase 2 Interventional

Informing Oral Nicotine Pouch Regulations to Promote Public Health

NCT06315881
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Biospecimen Collection, Cigarette, Nicotine Oral Pouch, Smokeless Tobacco, Survey Administration, Text Message-Based Navigation Intervention
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Results available

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

NCT02858401
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vesatolimod, Placebo, ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis

NCT01749787
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PRTX-100 at 1.5 mcg/kg, PRTX-100 at 3.0 mcg/kg, PRTX-100 at 6.0 mcg/kg, PRTX-100 at 12.0 mcg/kg, PRTX-100 at 240 mcg, Placebo, PRTX-100 at 420 mcg
Drug
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Coeur d'Alene, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NCT00002071
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 3:34 PM EDT
Terminated Not applicable Interventional

Helping Stroke Patients With ThermoSuit Cooling

NCT02453373
View directory record Official record
Conditions
Stroke, Brain Ischemia
Interventions
ThermoSuit Cooling Induction, Magnesium Sulfate, tPA, Propofol, Etomidate, Neurothrombectomy
Device · Drug · Procedure
Lead sponsor
Life Recovery Systems
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
New Orleans, Louisiana • Danville, Pennsylvania • Wilkes-Barre, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Not applicable Interventional Results available

The Zeaxanthin and Visual Function Study

NCT00564902
View directory record Official record
Conditions
Age Related Macular Degeneration, Cognition Disorders
Interventions
3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
Drug · Dietary Supplement
Lead sponsor
Chrysantis, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 31, 2026, 3:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 3:34 PM EDT
Active, not recruiting Phase 2 Interventional

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

NCT01871766
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
4
States / cities
Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047645
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2007 · Synced Oct 31, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 31, 2026, 3:34 PM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

NCT03617172
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Misoprostol 100Mcg Tab, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 31, 2026, 3:34 PM EDT